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Abstract
Background: Recent reports indicate that in vitro drug screens combined with gene expression profiles (GEP) of cancer cell
lines may generate informative signatures predicting the clinical outcome of chemotherapy. In multiple myeloma (MM) a
range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan.
Consequently, the generation of predictive signatures for response to melphalan may have a clinical impact. The hypothesis
is that melphalan screens and GEPs of B-cell cancer cell lines combined with multivariate statistics may provide predictive
clinical information.
Materials and Methods: Microarray based GEPs and a melphalan growth inhibition screen of 59 cancer cell lines were
downloaded from the National Cancer Institute database. Equivalent data were generated for 18 B-cell cancer cell lines.
Linear discriminant analyses (LDA), sparse partial least squares (SPLS) and pairwise comparisons of cell line data were used
to build resistance signatures from both cell line panels. A melphalan resistance index was defined and estimated for each
MM patient in a publicly available clinical data set and evaluated retrospectively by Cox proportional hazards and Kaplan-
Meier survival analysis.
Principal Findings: Both cell line panels performed well with respect to internal validation of the SPLS approach but only
the B-cell panel was able to predict a significantly higher risk of relapse and death with increasing resistance index in the
clinical data sets. The most sensitive and resistant cell lines, MOLP-2 and RPMI-8226 LR5, respectively, had high leverage,
which suggests their differentially expressed genes to possess important predictive value.
Conclusion: The present study presents a melphalan resistance index generated by analysis of a B-cell panel of cancer cell
lines. However, the resistance index needs to be functionally validated and correlated to known MM biomarkers in
independent data sets in order to better understand the mechanism underlying the preparedness to melphalan resistance.
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Introduction
The alkylating agent, melphalan, is the backbone of current
therapy in MM. Since the 1990s, melphalan has been used in high
dose therapy (HDT) followed by autologous stem cell transplan-
tation (ASCT) [1] and has as such improved the response rate, as
well as prolonged event free survival (EFS) and overall survival
(OS) [2]. Even though the last years have seen considerable
improvements, the overall survival remains dismal and the disease
is considered incurable – mainly due to an initial refractory disease
or induced resistance resulting in disease relapse. Refractory
disease and early relapse is considered associated with the
development of melphalan resistance which is a complex
phenomenon not completely understood [3]. One possible strategy
for improving the knowledge about drug resistance is the
combined use of novel technologies including GEP and drug
screen in a preclinical malignant B-cell cancer cell line model [4].
The fundamental idea of recent studies on drug resistance has
been to categorize cell lines into sensitive, resistant and
intermediate groups based on drug dose response experiments
and subsequently to generate a genetic classifier or signature based
on microarray analysis. Publicly available data from the NCI60
cell line panel generated by the National Cancer Institute (NCI)
have been used extensively in such studies for various cancer types
and treatment regimes. However, the approach remains contro-
versial [5,6]. Several authors have argued that the performance
could be improved by a specific cell line panel. Such an approach
was used by Lee et al. [7] and Liedtke et al. [8] for bladder and
breast cancer tumors, respectively. The successful approach of Lee
et al. [7] was based on the selection of gene expressions for the
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19322organ specific cell lines which correlate with gene expressions in
patient material before developing their classifier by a misclassi-
fication-penalized posterior algorithm. However, Liedtke et al. [8]
were unable to predict the outcome of chemotherapy response
with an approach based on diagonal linear discriminant analysis
(DLDA) for classification.
The concept of the present study is that melphalan resistance in
MM can be studied in a preclinical model of malignant B-cell
cancer cell lines by combining drug screens and GEPs and
generate a gene signature for resistance, which clinically can be
validated by predicting the outcome for tumors analysed before
high dose melphalan and ASCT. Such a strategy involves intensive
data generation in the laboratory and is succeeded by use of data
management and advanced statistical analysis [5,6]. In the present
study, we have implemented reproducibility by scripting the entire
data analysis flow in R and Bioconductor.
In summary, the specific aims of this study were to develop a
melphalan resistance gene index by use of 1) the publicly available
cell line panel NCI60 or 2) a panel of B-cell cancer cell lines and 3)
to support the concept though available ‘‘on-line’’ microarrays and
clinical data set from MM patients treated with double high dose
melphalan [9].
Materials and Methods
The NCI60 Cell Line Panel
The NCI60 cell line screen method is developed by NCI and
serves to screen a large number of substances for cytotoxic activity.
The panel consists of 59 cell lines derived from distinct cancer
types [10,11]. The gene expression data and chemotherapy
sensitivity data are publicly available. For more information, see
the Online Information Section below. In the present study we
used the GI50 value as defined by NCI [12].
B-Cell Cancer Cell Lines and Culturing Conditions
The BCell panel consisted of 13 MM cell lines, 1 plasmacytoma
(PC) cell line and 4 diffuse large B-cell lymphoma (DLBCL) cell
lines. The cell lines were cultured under standard conditions at
37uC; in a humidified atmosphere of 95% air/5% CO2 with the
appropriate medium, fetal bovine serum (FBS) and 1% penicillin/
streptomycin addition. See Table S1. The cell lines were
maintained for a maximum of 20 passages to minimize any
long-term culturing effects. Penicillin/streptomycin 1%,
RPMI1640, IMDM and FBS were purchased from Invitrogen.
The cell lines KMM-1 and KMS-11 were obtained from JCRB
(Japanese Collection of Research Bioresources), and KMS-12-PE,
KMS-12-BM, LP-1, MM1S, MOLP-2, MOLP-8, NCI-H929,
OPM-2, RPMI-8226, U-266, AMO-1, DB, HT and SU-DHL-4
from DSMZ (Deutsche Sammlung von Mikroorganismen und
Zellkulturen). The cell line MM1S was provided by Steven T.
Rosen [13], RPMI-8226 LR5 by William S. Dalton [14] and
OCI-Ly7 by Hans Messner [15].
Melphalan Dose Response Experiments
The cell number in the culture was determined by absorbance
measurements (CellTiter 96 Aqueous One Solution Reagent,
Promega) as described by the manufacturer. The linear relation-
ship between absorbance and cell number was obtained by seeding
cells in 96-well plates with the appropriate medium at concentra-
tions ranging between 15–60000 cells/well. The 18 cell lines were
incubated for 24 hours before the addition of 18 increasing
concentrations of melphalan in triplicates. All wells were seeded
with cells but border effects were circumvented by including only
non-border wells for analysis. The melphalan was resolved in
ethanol resulting in a final ethanol concentration of 0.06% in the
medium. The relative cell number was measured 48 hours after
the addition of melphalan using the CellTiter reagent and the
Optima-Fluostar (BMG LABTECH) at 492 nm. To achieve high
reproducibility, the whole experiment was repeated at least twice
utilizing new freeze stocks of the individual cell lines.
RNA Microarray Analysis
All GEPs were performed using the Affymetrix microarray
platform and standard procedures. Total RNA was extracted
using Invitrogen TRIzol Reagent combined with Qiagen RNeasy
Mini kit. The quality was checked by Agilent 2100 Bioanalyzer.
The samples were prepared for hybridization to Affymetrix
GeneChip HG-U133 Plus 2.0 arrays after the manufacturer’s
instruction and .CEL-files were generated by Affymetrix Gene-
Chip Command Console Software (AGCC) and deposited at the
NCBI Gene Expression Omnibus (GEO) repository. The data
fulfil the requirements of being MIAME compliant. For more
information, see the Online Information Section.
Arkansas and Hummel Cohorts of MM and DLBCL
Patients
Gene expression data, EFS, and OS data for 565 patients
diagnosed with progressive or symptomatic MM are publicly
available. For more information, see the Online Information
Section. The data set is known as the ‘‘Arkansas data’’ [16]. The
patients were enrolled by The Myeloma Institute for Research and
Therapy, University of Arkansas, School of Medical Sciences, and
they were part of a larger study with the purpose to investigate
whether thalidomide in combination with HDT can prolong
survival among patients with MM [9]. The 565 patients were
treated according to the total therapy two (TT2) or total therapy
three (TT3) protocol including double high dose melphalan and
ASCT.
The data set known as the ‘‘Hummel data’’ [17] was used in the
present study to test the specificity of the identified resistance
index. The 87 patients were diagnosed with DLBCL and received
a CHOP-like (cyclophosphamide, doxorubicin, vincristine, and
prednisone) induction treatment. Gene expression and OS data
are publicly available as well (for more information, see the Online
Information Section).
Statistical Analysis
Full documentation of the statistical analysis is provided by a
Sweave document, see Text S1. Sweave is a feature in the
statistical programming language R that enables the integration of
R code into LaTex and thereby it provides reproducible data
analysis and research [18]. All statistical analyses were done with
R [19] version 2.12.1 and a number of Bioconductor [20]
packages. Detailed session information is contained in Text S1.
Melphalan Dose Response Analysis. The absorbance
values originating from the dose response experiments were
background corrected and averaged over replicates. Eventual
outliers among the triplicated cell concentrations were removed
by Grubbs’ test [21] (approximately 0.5%, see Text S1). Relative
growth inhibition curves were calculated for each concentration
relative to the untreated control, whereafter a piecewise linear
growth curve was modelled. Through visual inspection, five
extreme values were removed (Figure S1). The GI50 values of the
cell lines in the BCell panel were defined as the first point at
which the growth curve drops below the 50% level. Data were
averaged over the replicated cell line measurements to perform
this analysis. The uncertainty of the GI50 values was assessed by
Melphalane Resistance Index
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calculation of all the GI50 values 200 times. The 10-fold
logarithm of the GI50 values was transformed to the log10 mM-
scale for both cell line panels and used as a melphalan resistance
index – in the following denoted the NCI60 index and BCell
index, respectively. As a means to distinguish between sensitive,
intermediate and resistant subjects (cell lines or individuals) in a
population, we chose the criterion of Havaleshko et al. [22],
where a subject is resistant if its resistance index exceeds the 75
percentile of the population. Similarly, we defined a subject to be
sensitive if its resistance index was less than the 25 percentile of
the population. The remaining subjects were characterized as
having intermediate resistance.
Microarray Pre-processing. The BCell .CEL-files and the
downloaded NCI60 .CEL-files were background corrected and
normalized by the just.rma function from the affy package. All
RMA-normalized arrays passed the statistical quality control
provided by the function arrayQualityMetrics in the R-package
arrayQualityMetrics [23]. As the NCI60 panel was analyzed on
the HG-U133a array and BCell on the HG-U133 Plus 2.0 array,
focus was on probes only present on the HG-U133A array. The
Arkansas data were also background corrected and normalized
with just.rma.
Differential Expressions. Following the unspecific filtering
of the gene expression data, the cell lines were ranked as resistant,
intermediate or sensitive according to their GI50 values.
Transcripts that expressed significant differences between the
groups of the most sensitive and most resistant cell lines were
determined using moderated F-tests as implemented in the
Bioconductor package limma [24]. Genes with a P-value below
0.05 were considered to have predictive value. The P-values were
deliberately chosen instead of false discovery rates as the purpose
was to construct a resistance classifier and not to detect
differentially expressed genes. The differentially expressed genes
were scaled to have zero mean and standard deviation one. A
classifier was built by the scaled genes and linear discriminant
analysis (LDA) as implemented in the R-package sda [25]. To
avoid difficulties inverting large covariance matrices, a maximum
of 400 genes in sda was chosen.
Multivariate Regression. The genes were filtered according
to sure independence screening (SIS), i.e. all genes were ranked
according to the Pearson correlation coefficient between its gene
expression and resistance index. All genes, for which the P-value of
the test for zero correlation was above 0.05, were considered for
dimensionality reduction by SPLS [26]. To obtain sparsity, SPLS
penalizes the transformed input vectors by forcing small
coefficients to be zero. The pure SPLS formulation contains four
tuning parameters, however, according to Chun et al. [26], a
simple SPLS regression formulation, which only depends on one
parameter g, is controlling the sparsity of the solution and the
number of hidden components K. For particular choices of the
regularization parameter g and the hidden components K the
performance was evaluated by leave-one-out cross-validations.
The optimal configuration of the parameters was chosen to be the
set minimizing the mean squared prediction error (MSPE). Once
the optimal parameters have been chosen internally from the cell
lines, the resistance index can be predicted for the subjects through
a linear combination of the scaled gene expressions with the
coefficients estimated by SPLS [27]. The SPLS analysis and
predictions are performed with the R-package spls provided by
Chun et al. [26].
Independent Filtering. It is well-known that independent
filtering increases detection power for high-throughput
experiments [28]. To investigate whether independent filtering
would increase accuracy and prediction error, an unspecific
filtering, leaving out genes with low variation over the NCI60 and
BCell gene expressions, were carried out with the function nsFilter
from the Bioconductor package genefilter. The cut-off values
varied between 0% and 100% and we chose the cut-off value
which performed best with respect to cross-validated accuracy for
the LDA and MSPE for SPLS. In order to investigate whether any
predictive power remained after filtering, cross-validation was
performed for the chosen parameters.
Survival Analysis. Kaplan-Meier survival analysis, logrank
test and Cox proportional hazards models were calculated with
functions from the R-package survfit. A nonlinear relationship
between the predicted response to treatment and the resistance
index was noticed and the relationship was estimated by restricted
cubic splines (RCS) by means of the R-package Design [29]. The
significance level is set to 0.05 and the hazard ratios (HR) are given
with 95% confidence intervals.
Online Information
Details on the required and deposited on-line information are
described below.
The BCell Gene Expression Data. .CEL files for the 18 cell
line microarrays have been deposited at http://www.ncbi.nlm.nih.
gov/geo/ under GEO accession number GSE22759. The data
fulfil the requirements to be MIAME compliant.
The NCI60 Gene Expression Data. .CEL-files for the
NCI60 cell line microarrays were downloaded from http://
www.ncbi.nlm.nih.gov/geo/ under GEO accession number
GSE5720 by selecting the subset of data originating from the HG-
U133A array. The cell line IGROV1 is provided in dublicates – in
the present study replicate A21 is used. The data fulfil the
requirements to be MIAME compliant. Notice that we have
renormalized the .CEL files as described in the Materials and
Methods Section.
The NCI60 DTP Data. The DTP human tumor cell line
screening data (August 2008 release) were obtained by
downloading the file cancer60gi50.lis from the website: http://
dtp.nci.nih.gov/docs/cancer/cancer data.html. Parts of the script
for extracting NCI60 drug response have been developed by
Kevin Coombes and Keith Baggerly and can be downloaded from
the website http://bioinformatics.mdanderson.org/Supplements/
ReproRsch-Chemo/.
The Arkansas Gene Expression and Clinical Data. .CEL
files for the gene expression data and clinical information are
available at http://www.ncbi.nlm.nih.gov/geo/ under GEO
accession number GSE24080. The data fulfil the requirements
to be MIAME compliant. The .CEL files are renormalized as
described in the Materials and Methods Section.
The Hummel Gene Expression and Clinical Data. .CEL
files and clinical information are available at http://www.ncbi.
nlm.nih.gov/geo/ under GEO accession number GSE4475. The
data fulfil the requirements to be MIAME compliant. The .CEL
files are renormalized as described in the Materials and Methods
Section.
Results
The NCI60 Panel Resistance Index
In brief summary, dose response data for melphalan were
downloaded. A plot of the data is seen in Figure S2. The 59 cell
lines showed GI50 values ranging from 25.77 to 23.99 on the
log10 mM/ml scale - the most sensitive cell line being SR and the
most resistant cell line being A498.
Melphalane Resistance Index
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Dose response experiments were carried out, and plots of the
data as well as fitted curves are illustrated in Figure 1A. The 18 cell
lines showed GI50 values ranging from 26.02 to 24.13 on the
log10 mM/ml scale - the most sensitive cell line being MOLP-2 and
the most resistant cell line being RPMI-8226 LR5. Figure 1B
shows box plots of the mean GI50 value from re-sampled dose-
response curves for all 18 B-cell cancer cell lines. As no clear
distinction between a resistant and sensitive group of cell lines was
detected, the 25%/50%/25% split described in the Materials and
Methods Section was chosen, i.e. the five cell lines with the lowest
GI50 values were denoted sensitive and the five cell lines with the
highest GI50 values were denoted resistant.
Classifier Based on LDA
For the NCI60 panel, an LDA based classifier was built as
outlined in the Materials and Methods section, for details see Text
S1. The LDA based classifier showed poor internal validation
(Figure S3). The optimal accuracy (determined by leave-one-out
cross-validation) of 0.6 was obtained for the BCell panel at a
filtering rate of 0.95, in which case the moderated F-test gave 159
genes (Table S2). LDA was used to combine the 159 genes to
develop a classifier. The classifier showed 60% overall leave-one-
out-cross-validation accuracy for the cell lines from which it was
developed.
Cross-Validating the SPLS Model
After the unspecific filtering steps were attained, SPLS was used
to achieve specific filtering. In order to avoid over-fitting and noise
contributing genes, the number of hidden components and
probesets were chosen by leave-one-out cross-validation. The
optimal number of probesets and components were found at the
values where the minimal MSPE was attained. For the NCI60
panel, a reasonable internal validation was observed (Figure S4).
For the BCell panel, two hidden components and 19 probesets
provided the best MSPE (Figure S5). The leverage of a single cell
line on the prediction model was investigated by plotting the
predicted resistance value originating from the leave-one-out-
cross-validation versus the measured resistance index (Figure S6).
The most sensitive and resistant cell lines MOLP-2 and RPMI-
8226 LR5, respectively, turned out to be high leverage points.
Stability Evaluation
To see how SPLS regression copes with noise, the BCell panel
was used to select 20 probesets randomly among the 100 probesets
with the highest marginal association (absolute value of the
Pearson correlation coefficient) with the resistance index. In order
to keep the dependence structure between the probesets intact,
these were all randomly perturbed, except for the 20 probesets.
The coefficients of the probesets are shown as a function of the
regularization parameter g in Figure S7. For this example, the
optimal number of sparse partial least squares components was
K=3 and the optimal regularization parameter was g=0.83.
Eleven probesets were chosen, which demonstrates an average
sensitivity of 55%, a specificity of 99% and a false discovery rate of
63%. The experiment was repeated 100 times and gave in average
a sensitivity of 54%, a specificity of 99% and a false discovery rate
of 67%.
Comparison of the most Sensitive and Resistant Cell
Lines
Due to the high influence of the most sensitive cell line, MOLP-
2, and the most resistant cell line, RPMI-8226 LR5, a direct
comparison of these two cell lines was made. This was done by
sorting the genes according to their absolute difference in gene
expression and choosing (quite arbitrarily) the 100 genes with the
highest absolute differential expressions. A predictive resistance
index was constructed by taking the difference in gene expressions
as weight. The genes and their weights are shown in the
supporting information (Table S3).
External Validation on Clinical Samples
EFS and OS were chosen as end points with the hypothesis that
melphalan resistance is correlated to these end points. For the
Figure 1. Melphalan dose-response summary. A) Averaged dose-response curves for each cell line. B) Box plot of 200 resampled GI50 values for
each cell line. The cell lines are ranked according to their estimated GI50 value.
doi:10.1371/journal.pone.0019322.g001
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model consisting of the two influential cell lines in the BCell panel
were used to estimate the melphalan resistance index for each of
the Arkansas patients.
For the LDA based predictions based on the NCI60 panel no
significant difference was observed with respect to OS and EFS for
the predicted sensitive, intermediate and resistant groups of
patients (Figure S8 and S9). For the NCI60 and SPLS based
predictions no significant difference was found for the predicted
sensitive, intermediate and resistant groups as well as the predicted
log relative hazard of OS and EFS for the Arkansas patient data.
See Figure 2A and C and Figure 3A and C, respectively.
For the BCell panel based SPLS model, the Kaplan-Meier
survival analysis is shown in Figure 2B and Figure 3B to illustrate
the distinction between the predicted resistant, intermediate and
sensitive groups for the Arkansas data. We detected a significant
difference in OS (P-value,0.001) and EFS (P-value,0.001) for
the three groups of patients. A Cox proportional hazards model
was used to detect that patients predicted melphalan sensitive have
significantly superior survival (HR=2.9 [2.41: 3.35]) and longer
Figure 2. OS analysis for the Arkansas data. A) Kaplan Meier survival curves based on NCI60. B) Kaplan Meier survival curves based on BCell. The
samples are categorized into a 25% most sensitive risk group, an intermediate risk group of 50% and a 25% high risk group, based on the melphalan
resistance index. The P-value is the logrank test for no difference in survival curves. C) Log relative hazard as function of the NCI60 resistance index. D)
Log relative hazard as a function of the BCell resistance index. The P-value is the maximum likelihood test for no RCS-association between log relative
hazard and resistance index and the dashed lines represent 95% confidence intervals.
doi:10.1371/journal.pone.0019322.g002
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patients for the BCell panel. The log relative hazards versus a
RCS-model for the resistance index are depicted in Figure 2D and
Figure 3D for the Arkansas OS and EFS data, respectively. There
is a significant tendency of shorter time to death (P-value,0.001)
and relapse (P-value,0.001) with increasing resistance index for
the BCell panel.
The LDA-classifier was used to predict whether the patients
in the Arkansas cohort of patients were sensitive or resistant
towards melphalan. A significant difference for both the OS (P-
value=0.006) and EFS (P-value,.001), with respect to the
BCell panel derived LDA classifier, was detected (Figure S10
and S11).
A significant difference in OS (P-value=0.004) and EFS (P-
value,0.001) between the patients categorized with respect to the
two influential cell lines were also shown (Figures S12 and S13).
Potential Marker Transcripts
SPLS with the optimal choices g=0.82 and K=2 identified 19
probesets with non-zero coefficients. Probesets, gene symbols and
names, biological function as well as chromosome locations and
regression weights are listed in Table 1.
Figure 3. EFS analysis for the Arkansas data. A) Kaplan Meier survival curves based on NCI60. B) Kaplan Meier survival curves based on BCell.
The samples are categorized into a 25% most sensitive risk group, an intermediate risk group of 50% and a 25% high risk group, based on the
melphalan resistance index. The P-value is the logrank test for no difference in survival curves. C) Log relative hazard as function of the NCI60
resistance index. D) Log relative hazard as a function of the BCell resistance index. The P-value is the maximum likelihood test for no RCS-association
between log relative hazard and resistance index and the dashed lines represent 95% confidence intervals.
doi:10.1371/journal.pone.0019322.g003
Melphalane Resistance Index
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For the BCell panel, no significant association between the
SPLS based resistance index and OS was found for the Hummel
data set (Figure S14 and S15).
Discussion
Motivated by the clinical importance of melphalan therapy, we
have combined in vitro drug screens and microarray data of B-cell
cancer cell lines and identified a melphalan resistance index
comprised of 19 genes which may be related to tumor biology. In
order to validate the resistance index it was tested in a publicly
available retrospective data set consisting of GEP data from the
myeloma tumor of MM patients receiving treatment including
high dose melphalan and a DLBCL trial, where patients never
received melphalan treatment.
Several reports have used publicly available GEPs and in vitro
drug response information from the NCI to develop drug-specific
pharmacogenomics response predictors. However, the idea of cell
line derived predictors is controversial and has been criticized.
Despite methodologically and conceptually difficult factors
involved in this strategy, it has not discouraged us to explore
similar avenues for molecular predictor discovery in MM and
multivariate bioinformatics tools. During the implementation of
the present strategy, we have identified several of such factors
related to the drug screen assay, the statistical approach, the
function of the identified genes, and most importantly, the clinical
validation as discussed below.
Firstly, the use of other toxicity measures than GI50 might as well
be relevant and reflect other biological mechanisms. Moreover, the
drug screen assay depends on the inhibition of cell proliferation
which is a central player in the efficacy of the selected drug.
However, other biological functions like apoptosis, cell differenti-
ation and DNA repair may also be involved in the drug effects.
Secondly, in high dimensional classification and regression
techniques it is unavoidable that some of the genes contribute with
noise to the clinical predictions. The noise was expected to be
minimized using a sparse version of PLS where the number of hidden
components and transcripts were selected by leave-one-out cross-
validation. A reasonable sensitivity and specificity were attained by
stability evaluation. However, also a high false discovery rate was
achieved, but one should notice that the simulation example was
designed for marginal association and not for optimal performance
with respect to SPLS. An important by-product of the multivariate
statistical analysis was the emphasizing of influential observations.
As described below, further elimination of false positive genes
may be pursued by gene enrichments and functional studies. It is
important to note that during the development of the resistance
index signature, we made several selections with regards to the
employed statistical methods and other decisions may have
resulted in similar or better results for the cell lines in general
and NCI60 in particular.
Thirdly, melphalan is an alkylating agent that introduces inter-
strand cross-links in DNA, and it could therefore be expected that
some of the genes involved in the melphalan resistance index
would be linked to DNA damage response by the Fanconi
anaemia (FA)/BRCA pathway as described by e.g. Yarde et al. [3]
and Chen et al. [30], or by other DNA damage repair pathways.
The resistance index, however, was based upon gene expression
levels prior to drug treatment, and a drug-induced activation of the
DNA repair response would therefore not be detected. In general,
the genes in Table 1 encode a functionally diverse group of genes
coding for proteins which are involved in numerous key pathways.
This indicates that several factors are involved in determining the
level of preparedness of a malignant cell to resist melphalan.
Interestingly, however, three of the genes in Table 1 (FBXW7,
USP6, and UBE2J1) are involved in ubiquitin regulated pathways
[31–33] and DNA damage responses have been shown to be
Table 1. The generated probesets predicting melphalan resistance.
U133 ID Gene Symbol Name Location Weight
205990_s_at WNT5A Wingless-type MMTV integration site family, member 5A 3p21-p14 20.065
203708_at PDE4B Phosphodiesterase 4B, cAMP-specific 1p31 20.053
201990_a_at CREBL2 cAMP responsive element binding protein-like 2 12p13 20.046
218751_s_at FBXW7 F-box and WD repeat domain containing 7 4q31.3 20.044
201889_at FAM3C family with sequence similarity 3, member C 7q31 20.039
206405_x_at USP6 USP6 N-terminal like 17p13 20.038
219049_at CSGALNACT1 Chondroitin sulfate N- acetylgalactosaminyltransferase 1 8p21.3 20.037
205862_at CREB1 cAMP responsive element binding protein 1 2p25.1 20.034
219748_at TREML2 Triggering receptor expressed on myeloid cells-like 2 6p21.1 20.033
204786_s_at IFNAR2 Interferon (alpha, beta and omega) receptor 2 21q22.1,21q22.11 20.033
204204_at SLC31A2 Solute carrier family 31 (copper transporters), member 2 9q31-q32 20.025
217825_s_at UBE2J1 Ubiquitin-conjugating enzyme E2, J1 (UBC6 homolog, yeast) 6q15 20.020
213555_at RWDD2A RWD domain-containing protein 2A-like 6q14.2 20.019
212122_at RHOQ Ras homolog gene family, member Q 2p21 20.016
203895_at PLCB4 Phospholipase C, beta 4 20p12 20.015
202043_s_at SMS Spermine synthase Xp22.1 0.011
217104_at ST20 Suppressor of tumorigenicity 20 15q25.1 0.012
212055_at C18orf10 Chromosome 18 open reading frame 10 18q12.2 0.025
221210_s_at NPL N-acetylneuraminate pyruvate lyase 1q25 0.032
doi:10.1371/journal.pone.0019322.t001
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Greenberg [34]). Kimura et al. [35] have shown that DNA
damage can induce FBXW7 expression via a p53-dependent
pathway, wherefore it would be interesting to investigate if
FBXW7 expression is linked to melphalan sensitivity through a
DNA damage response pathway. In addition, the function of Wnt-
5a is highly dependent upon ubiquitin proteasome pathways [36]
and the gene is significant in cancer development and is active
during embryogenesis, hematopoietic stem cell growth, cell
differentiation and tissue development and has been documented
to be of biological relevance in MM [37].
Other of the genes in Table 1 represent interesting candidates
for further investigation, including CSGALNACT1 which at high
expression levels previously has been shown to be associated with
improved prognosis for MM patients treated with melphalan [38].
CSGALNACT1 encodes for a protein involved in the synthesis of
chondroitin sulphate [39] – a component of Syndecan-1 (CD138)
[40] which is known to have a major impact in MM pathogenesis.
Finally, this study introduces a melphalan resistance index
predicting EFS and OS of MM patients treated with the double
high dose melphalan in the transplantation strategies described as
TT2 and TT3. A number of endpoints define the response to
melphalan treatment, e.g. immediate response, EFS or OS [41] –
each of these reflecting an effect on the biology of the malignant
clone. In the study of melphalan it is important to recognize that the
remission status is a difficult end point for evaluation as it is also
influenced by an effect of the induction therapy and maintenance.
In summary, a gene expression signature capable of predicting
response to melphalan therapy in a focused cell line panel has been
established by use of SPLS. The utility of the predictor was
retrospectively validated on data sets from patients diagnosed with
MM and treated with high dose melphalan as well as on a control
study of patients with DLBCL never treated with melphalan. The
lack of association between predicted melphalan resistance and
OS in the DLBCL study suggests that the resistance index is
melphalan specific and our future studies will address this for MM
patients in specific European clinical trial data sets.
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